Adverse Reactions: Sibutramine - increased cardiovascular risksSibutramine voluntarily withdrawn from Canadian and American markets in October 2010. Window to the world Calcium channel blocker–macrolide interaction: dangerous and underappreciated Azithromycin preferred in older patients receiving a CCB. Pomegranate may benefit dialysis patients Study links the fruit’s juice with reduced inflammation and hospitalizations due to infections and heart troubles Avoid statins in patients with intracerebral hemorrhage Uncertain whether statins advisable in patients at high risk for ICH. New drugs get a rise out of HDL Phase II trials look promising, but larger outcome studies needed Cholesterol deposits on eyelids give insight into heart disease The eyes have it—a clue to heart disease, that is. Stillbirth and repeat miscarriages carry heart attack risk Thelin (sitaxsentan): PAH drug withdrawn worldwide Pfizer Canada is voluntarily withdrawing Thelin from the market worldwide due to concerns about hepatotoxicity. Lowering urate cuts cardiovascular deaths Hyperuricemia deserves more aggressive treatment, researcher says First Previous 70 71 72 73 74 Next Last
